You are here: Industry Insights > CP-COV03

News List

Hyundai Bioscience finds combination therapy effective against Covid-19 Pharmaceutical-Technology
December 09, 2021
Hyundai Bioscience has reported that a combination of the niclosamide-based oral antiviral drug candidate, CP-COV03, with anti-inflammatory therapy, dexamethasone, showed to be effective in people with severe Covid-19 in a study.
CP-COV03, a niclosamide-based oral antiviral drug, under study as possible cure for COVID-19 variants prnasia
December 08, 2021
CP-COV03 is a broad-spectrum antiviral drug candidate, developed by Hyundai Bioscience to treat COVID-19. Its active pharmaceutical ingredient is niclosamide, an anthelmintic drug...
A 'Game Changer' COVID-19 drug from Korea was introduced in a world class academic journal prnasia
May 24, 2021
Hyundai Bioscience announced on the 24th that CNPharm, its major shareholding bio tech company, published an article containing the research results of CP-COV03, a Niclosamide-based oral treatment for COVID-19 based on its proprietary oral formulation ...
Hyundai Bioscience leads in the repurposing of Niclosamide prnasia
April 09, 2021
A research paper by a South Korean bio tech company that demonstrated the drug repurposing of Niclosamide, an anthelmintic known to have excellent therapeutic efficacy against novel coronavirus infection (COVID-19), was published in the world-renowned ...
Hyundai Bioscience announced that its COVID-19 oral drug solved Niclosamide's inhibitory concentration problem prnewswire
December 09, 2020
Hyundai Bioscience released a report on December 8th that CP-COV03, its new COVID-19 oral drug candidate, successfully demonstrated a 100% inhibitory concentration level in the blood (IC100) for 12 hours against viral activity with a single ...